Eli Lilly and Company (NYSE:LLY) Shares Bought by WealthShield Partners LLC

WealthShield Partners LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 9.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,804 shares of the company’s stock after purchasing an additional 339 shares during the period. WealthShield Partners LLC’s holdings in Eli Lilly and Company were worth $3,444,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Tidemark LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at about $29,000. Core Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the last quarter. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $32,000. Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $37,000. Finally, St. Johns Investment Management Company LLC grew its holdings in Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after buying an additional 37 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

LLY traded down $7.87 during midday trading on Wednesday, hitting $946.61. 1,024,850 shares of the company traded hands, compared to its average volume of 3,077,188. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company has a market capitalization of $899.66 billion, a price-to-earnings ratio of 140.80, a PEG ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The business has a 50 day simple moving average of $887.63 and a two-hundred day simple moving average of $816.72.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. Argus raised their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the company from $725.00 to $1,025.00 in a report on Monday, August 12th. Jefferies Financial Group upped their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Finally, Barclays boosted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $961.76.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares in the company, valued at $20,835,194.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold 1,120,089 shares of company stock valued at $990,278,343 over the last ninety days. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.